Subsequent Kaplan-Meier survival analysis on the clinical relevance of EFTUD2 in CRC, further revealing that patients with high expression levels of EFTUD2 had shorter OS and disease-free survival (DFS) compared with those with low EFTUD2 expression (OS: P = 0.001; DFS: P = 0.005, Fig. 2A and B). Here, EFTUD2 is linked to colorectal carcinoma.